Clinical Practice Session
Evidence-Based Updates in the Diagnosis and Management of Dysnatremia
October 23, 2026 | 10:30 AM - 12:30 PM
Location: Mile High Ballroom 1D, Convention Center
Session Description
This session provides a comprehensive update on dysnatremias, moving beyond traditional physiology to evidence-based practice. Experts debate the utility of the "DDAVP (desmopressin) clamp" strategy, present new paradigms for diagnosing diabetes insipidus (arginine vasopressin [AVP] deficiency) using copeptin, evaluate effective therapies for chronic hyponatremia, and discuss the latest mechanisms of drug-induced hyponatremia.
Learning Objective(s)
- Evaluate the safety and efficacy of emerging therapeutic strategies for severe hyponatremia to optimize correction rates, specifically comparing the "DDAVP clamp" method with intermittent bolus therapy
- Discuss the novel copeptin-based diagnostic algorithm for accurately differentiating between AVP deficiency, AVP resistance, and primary polydipsia in patients presenting with polyuria and hypernatremia
- Identify the most effective treatment for significant chronic hyponatremia
- Describe the pathogenesis of drug-induced hyponatremia, such as thiazide-induced hyponatremia
Learning Pathway(s)
- Fluid‚ Electrolyte‚ and Acid-Base Disorders
Moderators
Presentations
- The "DDAVP Clamp" for Severe Hyponatremia: Is It Time to Change the Standard of Care?
10:30 AM - 11:00 AM
- First-Line Therapy for Chronic Hyponatremia: Drugs vs. Fluid Restriction
11:00 AM - 11:30 AM
- Thiazide-Induced Hyponatremia: Novel Mechanisms and Modern Management
11:30 AM - 12:00 PM
- Diabetes Insipidus (AVP Deficiency): New Era of Copeptin-Based Diagnosis
12:00 PM - 12:30 PM